|
Number
|
240
|
49
|
33
|
158
| |
|
Gender (n)
|
|
Male:Female
|
119:121
|
23:26
|
16:17
|
80:78
|
0.895
|
|
Age (year)
|
|
Median (range)
|
67 (36–83)
|
65 (38–79)
|
68 (36–78)
|
66 (41–83)
|
0.881
|
|
Pre-neoadjuvant therapy CA19–9 value (U/ml)
|
|
Median (range)
|
152.7 (2.0–87,100.0)
|
12.9 (2.0–36.4)
|
84.0 (39.5–1129.0)
|
344.8 (32.0–87,100.0)
|
0.151
|
|
Post-neoadjuvant therapy CA19–9 value (U/ml)
|
|
Median (range)
|
57.7 (2.0–37,370.0)
|
8.5 (2.0–30.0)
|
21.0 (8.1–33.0)
|
134.5 (38.0–37,370.0)
|
0.148
|
|
% decrease of CA19–9 value (%)
|
|
Median (range)
|
53.2 (−100.0–326.4)
|
14.7 (− 100.0–100.0)
|
75.6 (24.9–90.2)
|
54.1 (− 326.4–96.4)
|
<.0001
|
|
Post-surgical CA19–9 value (U/ml)
|
|
Median (range)
|
18.6 (2.0–3929.4)
|
7.0 (2.0–35.0)
|
9.3 (4.0–171.0)
|
35.1 (3.2–3929.4)
|
0.026
|
|
CA19–9 normalization after surgery, n(%)
|
|
yes
|
164 (68)
|
49 (100)
|
29 (88)
|
86 (54)
| |
|
no
|
76 (32)
|
0 (0)
|
4 (12)
|
72 (46)
|
<.0001
|
|
Post-surgical tumor size (mm)
|
|
Median (range)
|
27.0 (8.0–70.0)
|
24.5 (8.0–48.0)
|
28.0 (10.0–50.0)
|
28.0 (10.0–70.0)
|
0.026
|
|
Preoperative drainage, n (%)
|
|
yes
|
152 (63)
|
35 (71)
|
17 (52)
|
100 (63)
| |
|
no
|
88 (37)
|
14 (29)
|
16 (48)
|
58 (37)
|
0.187
|
|
NCCN resectability, n (%)
|
|
Resectable
|
132 (55)
|
32 (65)
|
21 (64)
|
79 (50)
| |
|
Borderline
|
108 (45)
|
17 (35)
|
12 (36)
|
79 (50)
|
0.096
|
|
Neoadjuvant therapy, n (%)
|
|
Systematic chemotherapy
|
115 (48)
|
27 (55)
|
11 (33)
|
77 (49)
| |
|
Chemoradiotherapy
|
125 (52)
|
22 (45)
|
22 (67)
|
81 (51)
|
0.145
|
|
Duration of neoadjuvant therapy (day)
|
|
Median (range)
|
69 (13–120)
|
69 (22–117)
|
71 (44–112)
|
68 (13–120)
|
0.569
|
|
RECIST, n (%)
|
|
Complete response
|
11 (5)
|
4 (8)
|
2 (6)
|
5 (3)
| |
|
Partial response,
|
33 (14)
|
11 (23)
|
7 (21)
|
15 (10)
| |
|
Stable disease
|
192 (80)
|
33 (67)
|
24 (73)
|
135 (85)
| |
|
Progressive disease
|
4 (1)
|
1 (2)
|
0 (0)
|
3 (2)
|
0.096
|
|
Operation, n (%)
|
|
Pancreaticoduodenectomy
|
160 (67)
|
33 (67)
|
26 (79)
|
101 (64)
| |
|
Distal pancreatectomy
|
80 (33)
|
16 (33)
|
7 (21)
|
57 (36)
|
0.256
|
|
N classification (UICC), n (%)
|
|
1
|
130 (54)
|
24 (49)
|
12 (36)
|
93 (59)
| |
|
0
|
110 (46)
|
25 (51)
|
21 (64)
|
64 (41)
|
0.042
|
|
Residual tumor, n (%)
|
|
R0
|
205 (85)
|
44 (90)
|
32 (97)
|
129 (82)
| |
|
R1
|
35 (15)
|
5 (10)
|
1 (3)
|
29 (18)
|
0.048
|
|
Adjuvant therapy, n (%)
|
|
yes
|
205 (85)
|
42 (86)
|
27 (82)
|
136 (86)
| |
|
no
|
35 (15)
|
7 (14)
|
6 (18)
|
22 (14)
|
0.826
|
|
Completion of adjuvant therapy, n (%)
|
|
yes
|
139 (67)
|
34 (83)
|
23 (85)
|
82 (59)
| |
|
no
|
68 (33)
|
7 (17)
|
4 (15)
|
57 (41)
|
0.002
|
